43 results about "CD70" patented technology

Provided herein are anti-idiotypic antibodies that specifically recognize anti-CD70 antibody portions, particularly anti-CD70 antibody portions present in recombinant receptors, including chimeric antigen receptors (CARs). The present disclosure further relates to the use of anti-idiotypic antibodies to specifically identify and / or select cells expressing such recombinant receptors, such as anti-CD70 CAR T cells. The present disclosure further relates to the use of anti-idiotypic antibodies to specifically activate such cells.

The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and / or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

The invention relates to a CD19 and CD70 targeted double-target chimeric antigen receptor and application thereof, the CD19 and CD70 targeted double-target chimeric antigen receptor comprises an extracellular antigen binding domain, a hinge region, a transmembrane domain, an intracellular costimulatory domain and an intracellular signal transduction domain, and the extracellular antigen binding domain has specific binding ability to CD19 and CD70. The double-target chimeric antigen receptor structure has a treatment effect of targeting double antigens or single antigens, can be used for preparing immune effector cells targeting CD19 and CD70, and provides a treatment or improvement approach for diseases related to CD19 and CD70 double expression or CD19 / CD70 single expression.

The application provides a construction method of a humanized keloid mouse model, comprising the following steps: BAC plasmid construction and preparation; superovulation of experimental mice and collection of zygotes; pronuclear microinjection of zygotes; post-injection embryo transplantation; genotype identification; breeding and genetic analysis; and verification of construction results of the humanized immune system by immunohistochemistry and immunofluorescence. In the application, peripheral blood mononuclear cells treated by sCD27 and skin around keloids (homologous cells and tissues) are transplanted into NSG-MHC-DKO immune-deficient mice with overexpression of CD70 genes, so that HLA rejection of different homologous immune cells and tissues can be avoided, the internal microenvironment of keloids and the interaction between the internal microenvironment and the immune system can be restored to the maximum extent, and the influence of immune factors on the occurrence and development of keloids can be realized in vitro. The application first discovers and verifies that the activation of the CD27-CD70 axis can promote the occurrence and development of keloids, and provides a suitable animal model for the research and development of anti-keloid drugs, especially immunotherapy.

Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically engineered cells in allogeneic cell therapy. Also provided are T cells that are genetically engineered with a CAR, such as a CD70-targeted CAR, and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

The invention relates to a CD70 and BCMA targeting dual-targeting chimeric antigen receptor and an application thereof. The CD70 and BCMA targeting dual-targeting chimeric antigen receptor has specific binding ability to CD70 and BCMA. The immune effector cell prepared on the basis of the double-targeting chimeric antigen receptor has the following advantages that the probability that tumor cells escape treatment by losing a single antigen is greatly reduced, and the targeting treatment effect is improved; a CD70 nano antibody sequence is used, so that the length of an insertion fragment is greatly shortened, and the development difficulty of a process end is reduced; and the polypeptide has excellent proliferation capacity, is beneficial to prolonging the in-vivo duration time, and plays a more remarkable anti-tumor role. The invention provides a treatment or improvement approach for diseases related to BCMA-CD70 expression.

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are genetically edited, for example, using Crispr / Cas, to modulate, reduce or otherwise eliminate expression of one or more endogenous genes. In several embodiments, the edited cells are engineered to express a chimeric antigen receptor targeting a tumor antigen, for example CD19, ligands of the NKG2D receptor, CD70, and / or BCMA, among others. In several embodiments, the editing enhances one or more aspects of the efficacy of the immune cells in cellular immunotherapy including cytotoxicity (e.g., ADCC) and / or persistence.

Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.

The present application relates to the technical field of multi-gene detection, and in particular to a set of capture probes for follicular lymphoma multi-gene detection, a kit and a detection analysis method ARID1A, ARID1B, ATM, ATP6V1B2, B2M, BCL10, BCL2, BCL6, BCL7A, BTG1, BTG2, BTK, CARD11, CCND3, CD58, CD70, CD79A, CD79B, CDK4, CDKN2A The capture probe set comprises capture probes for specifically binding to 74 follicular lymphoma related genes, and the capture probe set preferably comprises nucleotides with sequences as shown in SEQ ID NO. 1-937. The probe set of the present application can realize one-time detection of variation in the full exon region of 74 follicular lymphoma related genes in the sample to be detected in the same system, has high specificity, high average sequencing depth and wide coverage area.

CD70 binding proteins or ligands, particularly CD27 polypeptides, and particularly variant CD27 extracellular binding domain polypeptides, are provided wherein the CD27 amino acid sequence is altered. The CD27 polypeptides and / or domains thereof, particularly the extracellular binding domains thereof are useful in the diagnosis and treatment of various conditions, including in cancer and immunotherapuetics. The CD27 polypeptides and / or domains thereof, particularly the extracellular binding domains thereof may also be used in lymphoid cell-mediated, including T cell-mediated, therapy, in chimeric antigen receptor (CAR) therapy, and / or in therapy in combination with chemotherapeutics, radiation therapy, immune modulators, cancer vaccines, cancer antigens, or anti-cancer agents. Particular variant CD27 polypeptides, extracellular domains, and novel CAR constructs are provided.

The compositions and methods described herein relate to the use of a CRISPR / Cas9 system in combination with a CAR technology for improving the activity of anti-CD70 CAR-T cells. The engineered cells may comprise a genetic modification in one or more of the HLA-A, HLA-B, TRAC, CIITA, TGFBR2, or CD70 genes.

The disclosure is directed to methods and compositions for treating cancers characterized by cells comprising chimeric antigen receptors (CARs) that bind CD70 and T-cell engaging antibody molecules (TEAMs) that bind CD33, nucleic acid molecules encoding chimeric antigen receptors (CARs) that bind CD70 and / or TEAMs that bind CD33, and compositions and methods related thereto.

This article provides information on T cell receptor (TCR) fusion proteins (TFPs) containing a CD70 binding domain, T cells engineered to express one or more TFPs, antibodies that specifically bind to CD70, and methods of using them to treat diseases including cancer.

This application relates to methods for treating patients with reduced sensitivity to BCL-2 inhibitors. An antibody or antigen-binding fragment thereof that binds to CD70 is provided for treating myeloid malignancies in human subjects resistant to BCL-2 inhibitor treatment, and a method for treating myeloid malignancies in a subject, the method comprising (a) selecting a human subject with myeloid malignancies who has reduced sensitivity to or is refractory to BCL-2 inhibitors; and (b) administering the CD70-binding antibody or antigen-binding fragment thereof to the subject. In some embodiments, the myeloid malignancy is acute myeloid leukemia (AML). In some embodiments, the CD70-binding antibody is Cusatuzumab. In some embodiments, the BCL-2 inhibitor is co-administered with the CD70-binding antibody or antigen-binding fragment thereof. In some embodiments, the BCL-2 inhibitor is Venetoc.

The present disclosure relates to DNA constructs encoding CD19-specific chimeric antigen receptors (CARs) and other recombinant proteins, such as CD70-binding proteins or CD70-specific CARs, as well as engineered immune cells (e.g., CD19-specific CAR T cells or CD19 / CD70 dual CAR T cells) comprising the DNA constructs, methods of making the same, and uses thereof in therapeutic applications.

A population of genetically engineered T cells, comprising a disrupted protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene and optionally a disrupted TRAC gene, a disrupted β2M gene, and / or a disrupted CD70 gene. Also provided herein are methods for making such genetically engineered T cells and therapeutic uses thereof.

The application provides a monoclonal antibody targeting human CD70 and application thereof. Specifically, the application obtains a group of monoclonal antibodies targeting human CD70 from B cells of mice immunized by the application, the monoclonal antibodies have high affinity with CD70 protein on the surface of cells, and can block the interaction between CD27 protein and CD70 protein. In addition, the application also provides a fusion protein, CAR-T / NK / macrophage, immunoconjugate and the like containing the antibody, and the CAR-T cell has specific killing function to cells expressing CD70.

This disclosure relates to CRISPR-related systems and components for targeting, editing, and / or regulating CD70 (differentiation cluster 70) gene expression. This disclosure also relates to methods and applications relating to genetically modified cells, including T cells or T cell progenitor cells.

This invention belongs to the field of biomedical technology and discloses an anti-CD70 nanobody and its applications. Specifically, it discloses an anti-CD70 nanobody characterized by CD70 binding function and the ability to block the binding of the CD70-CD27 receptor ligand, and defines its specific amino acid sequence. This invention provides an anti-CD70 nanobody obtained by immunizing alpacas, exhibiting high affinity and specificity. It can be used for immunoblotting, enzyme-linked immunosorbent assay (ELISA) kits, flow cytometry detection and counting, and also for the treatment of diseases such as tumors and autoimmune diseases.

The present invention is directed to an engineered cell comprising a chimeric antigen receptor (CAR) on its surface specific for carbonic anhydrase XI (CAIX) and an antigen binding domain specific for cluster of differentiation 70 (CD70), and wherein the engineered cell is further engineered to express and secrete a bispecific antibody specific for PD-1 and an antigen binding domain specific for CTLA4.

The invention provides a nano antibody in targeted binding with CD70, a CAR-T cell and an application of the nano antibody and the CAR-T cell. Specifically, the invention provides a nano antibody (VHH) for targeted recognition of CD70 and a chimeric antigen receptor immune cell constructed based on the nano antibody. The invention also provides application of the nano antibody and the chimeric antigen receptor immune cell in treatment of CD70 related diseases.

Provided herein are polynucleotides, vectors, compositions and methods for preparing and using genetically modified immune cells that express a chimeric antigen receptor (CAR) and a CD70 short hairpin RNA (shRNA), as well as method of using such modified immune cells for treating diseases or disorders, such as cancer or autoimmune disorders.

Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.

The present invention provides conjugates of CD70 antibodies and / or antigen-binding portions thereof for use in the treatment of cancer and autoimmune diseases. TIFF2026503177000370.tif67140

The invention provides a nano antibody combined with CD70 and application of the nano antibody in the field of cell therapy. Specifically, the invention provides a nano antibody (VHH) for targeted recognition of CD70 and a chimeric antigen receptor immune cell constructed based on the nano antibody. The invention also provides application of the nano antibody and the chimeric antigen receptor immune cell in treatment of CD70 related diseases.

This invention provides a probe library and kit for detecting genetic risk gene mutations in viral infections, belonging to the field of gene detection technology. The probe library and kit designed in this invention achieve, for the first time, the simultaneous detection of all mutations in the following 51 genetic risk genes for viral infections: CARMIL2, CCL2, CD27, CD70, CIB1, CTPS1, CXCR4, CYBC1(C17orf62), DBR1, FCGR3A, FCHO1, ICAM1, IFIH1, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IL10, IL10RA, IL10RB, IL... The probe library and kit of this invention contain 18BP, IRF3, IRF7, IRF9, MAGT1, LIG1, MCM2, NOS2, OAS1, POLR3A, POLR3C, POLR3F, PRKCD, RASGRP1, SH2D1A, STAT1, STAT2, TBK1, TICAM1, TLR3, TLR7, TLR8, TMC6, TMC8, TNFRSF9, TRAF1, TRAF2, TRAF3, TYK2, UNC93B1, and XIAP. This invention's probe library and kit can be used for detecting genetic variations in the risk of viral infection in clinical settings, assessing an individual's genetic risk of viral infection, and has broad application prospects.

Compositions and methods for editing, e.g., altering, DNA sequences within the CD70 gene are provided. Compositions and methods for reducing or eliminating CD70 protein expression in a cell are provided. Compositions and methods for immunotherapy are provided.